期刊文献+

PTP1B和1,2-萘醌类抑制剂的分子动力学模拟 被引量:3

MD Simulations of PTP1B-Inhibitor Complex
在线阅读 下载PDF
导出
摘要 采用分子动力学和分子力学相结合的方法 ,研究了一类 1,2 萘醌类抑制剂与酪氨酸蛋白磷酸酯酶PTP1B之间的相互作用模式 .计算得到的抑制剂和靶酶之间的相互作用模式显示范德华相互作用、疏水相互作用以及氢键作用是主要的作用模式 .计算结果还表明抑制剂和PTP1B的相互作用能ΔE越低 ,抑制剂活性越高 .通过计算各种能量对ΔE的贡献 ,以及对复合物结构参数的分析 ,发现抑制剂和受体之间疏水相互作用是造成抑制剂活性差别的主要原因 . The interaction pattern between PTP1B (one kind of protein tyrosine phosphatase) and its inhibitors (1,2 naphthoquinone derivatives) was investigated by using molecular mechanics and molecular dynamics. From the calculations, it can be found that the van der Waals interactions, the hydrophobic interactions, as well as the H bonding interactions are crucial for ligand binding. Meanwhile, the calculated results show that the interaction energy, Δ E , is closely correlated with the activity of inhibitors. In addition, from the calculation of contribution of the van der Waals and electrostatic interactions to Δ E and the analyses of the predicted structures of the complex, we found that the difference of the activities of inhibitors is attributed to the hydrophobic interaction, which afford us important information for designing non acid PTP1B inhibitors.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2004年第2期148-152,共5页 Acta Chimica Sinica
基金 国家自然科学基金 (Nos.2 0 2 730 83 2 9992 590 )资助项目
关键词 1 2-萘醌类抑制剂 酪氨酸蛋白磷酸酯酶 PTPlB 分子动力学 相互作用 作用模式 糖尿病 PTP1B, 1,2-naphthoquinone derivative, MD simulation, inhibitor
  • 相关文献

参考文献15

  • 1Zhang, Z. Y. Curr. Opin. Chem. Biol. 2001, 5, 416.
  • 2Barford, D.; Flint, A. J.; Tonks, N. K. Science 1994, 263(11), 1397
  • 3Jia, Z.; Barford, D.; Flint, A. J.; Tonks, N. K. Science 1995, 268(23), 1754
  • 4Goldstein, B. J. J. Cell. Biochem. 1992, 31, 33.
  • 5Goldstein, B. J. Receptor 1993, 3, 1.
  • 6Defronzo, R. A.; Bonadonna, R. C.; Ferrannini, E. Diabetes Care 1992, 15, 318.
  • 7Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Hagen, J. H.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Science 1999, 283, 1544.
  • 8Klaman, L. D.; Boss, O.; Peroni, O. D.; Kim, J. K.; Martino, J. L.; Zabolotny, J. M.; Moghal, N.; Lubkin, M.; Kim, Y. B.; Sharpe, A. H.; Krongrad, A. S.; Shulman, G. I.; Neel, B. G.; Kahn, B. B. Mol. Cell Biol. 2000, 20, 5479.
  • 9Andersen, H. S.; Iversen, L. F.; Jeppesen, C. B.; Branner, S.; Norris, K.; Rasmussen, H. B.; Moller, K. B.; Moller, N. P. J. Biol. Chem. 2000, 275(10), 7101.
  • 10Iversen, L. F.; Andersen, H. S.; Moller, K. B.; Olsen, O. H.; Peters, G. H.; Branner, S.; Mortensen, S. B.; Hansen, T. K.; Lau, J.; Ge, Y.; Holsworth, D. D.; Newman, M. J. Biochemistry 2001, 40, 14812.

同被引文献38

  • 1蔡金艳,宫立孟,张勇慧,阮汉利,皮慧芳,吴继洲.金线莲化学成分的研究[J].中药材,2008,31(3):370-372. 被引量:28
  • 2王辰,王沥,杨泽.蛋白质酪氨酸磷酸酶1B(PTP1B)与2型糖尿病及肥胖的关系[J].遗传,2004,26(6):941-946. 被引量:8
  • 3何春年,王春兰,郭顺星,杨峻山,肖培根.福建金线莲的化学成分研究Ⅱ[J].中国中药杂志,2005,30(10):761-763. 被引量:89
  • 4关璟,王春兰,郭顺星.福建产金线莲中黄酮苷成分的研究[J].中草药,2005,36(10):1450-1453. 被引量:70
  • 5谢宗万.全国中草药汇编(下册).北京:人民卫生出版社,1992;392-393.
  • 6Zhang YH, Cai JY, Pi HF, et al. Antihyperglycemic activity of kinsenoside, a high yielding constituent from Anocctochilus roxburghii in streptozotocin diabetic rats. Ethnopharmacology,2007 ; 11 (4) : 141 - 145.
  • 7Wu JB, Lin WL, Hsieh CC et al. The hepatoprotective activity of kinsenoside from Anoectochilus formosanus. Phytother Res. ,2007 ;21 ( 1 ) : 58 -61.
  • 8Du X, Sun N, Tamura T et al. Higher yielding isolation of kinsonoside in Anoectochilus and its antihyperliposis effect. Biol Pharm Bull, 2001 ;24 (1): 65-69.
  • 9Elchebly M, Payette P, Michaliszyn E. Increased insulin sensitivity and obesity resistant in mice lacking the protein tyrosine phosphatasel B gene. Science, 1999 ;283 : 1544 - 15481.
  • 10Zhang X, Huang HH, Chen QH. A novel total synthesis of kinsenoside and goodyeroside A relying on the efficient reaction of the ehiral 2(5H) -furanones. J Asian Nat Prod Res. ,2005;7(5): 711 -721.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部